Novartis and Novo Nordisk cardiovascular drug failures may dampen industry momentum
Source Summary
Novartis and Novo Nordisk have each experienced failures of cardiovascular drugs in back-to-back announcements. Industry observers suggest these setbacks could have a dampening effect on the broader pharmaceutical field's development efforts.
Why it matters
Multiple drug failures from major pharmaceutical companies can influence investment and development decisions across the industry.
